期刊论文详细信息
Frontiers in Cardiovascular Medicine
Myocardial fibrosis in rheumatic heart disease: emerging concepts and clinical implications
Cardiovascular Medicine
Wishnu Aditya Widodo1  Teuku Muhammad Haykal Putra1  Quang Ngoc Nguyen2  Jack Wei Chieh Tan3  Sidhi Laksono4  Jagat Narula5  Rodrigo Rodriguez-Fernandez6  Maria Elfiana7 
[1] Department of Cardiology and Vascular Medicine, Jakarta Heart Center, Jakarta, Indonesia;Department of Cardiology, Hanoi Medical University, Hanoi, Vietnam;Department of Cardiology, National Heart Centre Singapore, Singapore, Singapore;Faculty of Medicine, Universitas Muhammadiyah Prof. DR. Hamka, Tangerang, Indonesia;Icahn School of Medicine at Mount Sinai, New York, NY, United States;International SOS, London, United Kingdom;Research Unit, Jakarta Heart Center, Jakarta, Indonesia;
关键词: myocardial fibrosis;    rheumatic heart disease;    Group A Streptoccocus;    cross reactivity;    LV dysfunction;   
DOI  :  10.3389/fcvm.2023.1230894
 received in 2023-05-29, accepted in 2023-07-03,  发布年份 2023
来源: Frontiers
PDF
【 摘 要 】

Rheumatic heart disease (RHD) remains a significant cardiovascular burden in the world even though it is no longer common in affluent countries. Centuries of history surrounding this disease provide us with a thorough understanding of its pathophysiology. Infections in the throat, skin, or mucosa are the gateway for Group A Streptococcus (GAS) to penetrate our immune system. A significant inflammatory response to the heart is caused by an immunologic cascade triggered by GAS antigen cross-reactivity. This exaggerated immune response is primarily responsible for cardiac dysfunction. Recurrent inflammatory processes damage all layers of the heart, including the endocardium, myocardium, and pericardium. A vicious immunological cycle involving inflammatory mediators, angiotensin II, and TGF-β promotes extracellular matrix remodeling, resulting in myocardial fibrosis. Myocardial fibrosis appears to be a prevalent occurrence in patients with RHD. The presence of myocardial fibrosis, which causes left ventricular dysfunction in RHD, might be utilized to determine options for treatment and might also be used to predict the outcome of interventions in patients with RHD. This emerging concept of myocardial fibrosis needs to be explored comprehensively in order to be optimally utilized in the treatment of RHD.

【 授权许可】

Unknown   
© 2023 Putra, Rodriguez-Fernandez, Widodo, Elfiana, Laksono, Nguyen, Tan and Narula.

【 预 览 】
附件列表
Files Size Format View
RO202310102302249ZK.pdf 27421KB PDF download
  文献评价指标  
  下载次数:1次 浏览次数:0次